In 2023, Ibn Al-Haytham led ANGINA, a post-marketing observational study evaluating the efficacy, safety, and tolerability of Anti-Angina® (Ranolizine) in patients with recurrent angina pectoris, many of them had not achieved adequate symptom control with first-line treatments alone.

📍Study Scope 
• Patients: 481
• Participating Doctors: 52
• Setting: Diverse outpatient environments across the country

Results:

Sublingual nitrate consumption decreased significantly from a mean of 3.69 uses per week at baseline to 1.08 at the second visit and 0.41 at the third visit (p <0.001). 

Angina frequency showed marked improvement, with the proportion of patients reporting no anginal episodes increasing from 0% at baseline to 37.6% at the second visit and 57.9% at the third visit.

Canadian Cardiovascular Society classification demonstrated progressive functional improvement. Class I classification (angina only during strenuous activity) increased from 11.6% at baseline to 50.1% at the second visit and 70.3% at the third visit, while Class IV (inability to perform any activity without angina) decreased from 6.2% to 0.9% to 0.4%.

Quality of life scores improved progressively, declining from 4.9 at baseline to 2.95 at the second visit and 2.23 at the third visit, reflecting substantial reduction in symptom burden (p <0.001).

Efficacy assessment revealed excellent outcomes in 58.8% of patients and good outcomes in 35.1% of patients with only 1.5% of patients reporting poor efficacy. 

Scientific Integrity: Our Commitment

Scientific credibility is a fundamental pillar of our corporate vision. We strive to integrate scientific transparency with local practical requirements. This approach ensures the delivery of accurate, reliable information to physicians and pharmacists, ultimately prioritizing patient interests and providing the highest possible standard of healthcare.